更新于：2024-11-04
Silodosin
赛洛多辛
更新于：2024-11-04
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (2006-01-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C25H32F3N3O4 |
InChIKeyPNCPYILNMDWPEY-QGZVFWFLSA-N |
CAS号160970-54-7 |
关联
101
项与 赛洛多辛 相关的临床试验Silodosin vs Placebo in the Treatment of Female Lower Urinary Tract Symptoms: A Randomized Controlled Trial
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Silodosin Tablets 4 mg manufactured by SRIPRASIT PHARMA CO., LTD., relative to Urief Tablets 4 mg, in healthy Thai male volunteers under fed condition
Prospective Randomized Controlled Trial to evaluate effectiveness of adjuvant Silodosin for Improving the Stone-Free Rate after Extracorporeal Shock Wave Lithotripsy in Renal Stones
100 项与 赛洛多辛 相关的临床结果
登录后查看更多信息
100 项与 赛洛多辛 相关的转化医学
登录后查看更多信息
100 项与 赛洛多辛 相关的专利（医药）
登录后查看更多信息
475
项与 赛洛多辛 相关的文献（医药）2024-11-01Annales Pharmaceutiques Francaises
Understanding the side effects of chronic silodosin administration via untargeted metabolomics approach
Article
作者: Kadioglu, Yucel ; Aydin, İsmail Cagri ; Erkayman, Beyzagul ; Senol, Onur ; Akman, Tugrul Cagri
BACKGROUND:
Precision medicine, which looks for high efficacy and low toxicity in therapies, has increased in popularity with omics technology. This work aims to discover novel and low-toxicity therapy options by examining the complex relationship between silodosin-induced side effects and the metabolomic profiles associated with its administration.
MATERIALS AND METHODS:
The plasma samples of the control group and silodosin-treated rats were analyzed by LC-Q-TOF-MS/MS. Employing XCMS and MetaboAnalyst software, MS/MS data processed to detect compounds and investigate metabolic pathways. MATLAB 2019b was used for data categorization and multivariate analysis. A thorough comparison of METLIN and HMDB databases revealed 41m/z values with significant differences between the drug-treated and control groups (p <0.01 and fold analysis≥1.5).
RESULTS:
According to multivariate data analysis, 17-β-estradiol, taurocholic acid, L-kynurenine, N-formylkynurenine, D-glutamine, L-arginine, prostaglandin H2, prostaglandine G2, 15-keto-prostaglandin E2, calcidiol, thromboxane A2, 5'-methylthioadenosine, L-methionine and S-adenosylmethionine levels changed significantly compared to the control group. Differences in the metabolisms of glycerophospholipid, tyrosine, phenylalanine, arachidonic acid, cysteine and methionine, and biosynthesis of phenylalanine, tyrosine, and tryptophan, and aminoacyl-tRNA have been successfully demonstrated by metabolic pathway analysis. According to this study, vitamin D, D-glutamine, and L-arginine supplements can be recommended to prevent side effects such as fatigue, intraoperative floppy iris syndrome, blurred vision, and dizziness in the treatment of silodosin. Silodosin treatment negatively affected the immune system by affecting the kynurenine and tryptophan metabolism pathways.
CONCLUSIONS:
The study is a guide for silodosin treatments that offer low side effects and high therapeutic effect within the scope of precision medicine.
2024-05-01Naunyn-Schmiedeberg's archives of pharmacology
Alpha1-adrenergic blockers selectively antagonize the contractions induced by 6-nitrodopamine in the human vas deferens
Article
作者: Guimarães, Renan Arthur Bosio ; Fregonesi, Adriano ; Antunes, Edson ; Oliveira, Denis Lima ; De Nucci, Gilberto ; Britto-Júnior, José ; de Oliveira Stocco, Gabriel Augusto ; Lima, Antonio Tiago ; Salgado Uramoto, Edson Hiroshi ; Quirino Junior, Gilberto
6-Nitrodopamine (6-ND) is released from human vas deferens and plays a modulatory role in the male ejaculation. Therapeutical use of α1-adrenoceptor antagonists is associated with ejaculatory abnormalities. To evaluate the effect of α1-adrenoceptor antagonists on the contractions induced by 6-ND, dopamine, noradrenaline, and adrenaline in the human epididymal vas deferens (HEVD). HEVD strips were suspended in glass chambers containing heated and oxygenated Krebs-Henseleit's solution. Cumulative concentration-response curves to catecholamines (10 nM-300 μM) were constructed in HEVD strips pre-incubated (30 min) with doxazosin (0.1-1 nM), tamsulosin (1-10 nM), prazosin (10-100 nM) and/or silodosin (0.1-10 nM). The effects of these α1-adrenoceptor antagonists were also evaluated in the electric-field stimulation (EFS, 2-32 Hz)-induced contractions. Doxazosin (0.1 nM) caused significant reductions in 6-ND-induced HEVD contractions without affecting the contractions induced by dopamine, noradrenaline, and adrenaline. Similar results were observed with tamsulosin (1 nM) and prazosin (10 nM). At these concentrations, these α1-adrenoceptor antagonists largely reduced the EFS-induced contractions. Silodosin (1 nM) caused concentration-dependent rightward shifts of the concentration-response curves to 6-ND but had no effect on the contractions induced by dopamine and adrenaline. Silodosin (0.1 nM) only inhibited the contractions induced by noradrenaline. Silodosin at 1 nM, but not at 0.1 nM, caused significant reductions in the EFS-induced contractions. The results reinforce the concept that 6-ND plays a major role in the human vas deferens contractility and indicate that the ejaculation disorders caused by doxazosin, tamsulosin, prazosin and silodosin cause in man, may be due to inhibition of the contractions induced by 6-ND rather than by the classical catecholamines dopamine, noradrenaline, and adrenaline.
2024-03-01Annales pharmaceutiques francaises
Development and validation of stability indicating RP-HPLC method for simultaneous estimation of silodosin and mirabegron in synthetic mixture
Article
作者: Surekha, Ninama ; Mishra, Shweta ; Chauhan, Ashlesha
The study focuses to validate and develop a precise, simple and accurate stability indicating RP-HPLC method for estimation simultaneously of and silodosin and mirabegron in synthetic mixture. The chromatographic separation was achieved by using Shimpack Solar C18 column (250×4.5mm, 5μm) with acetonitrile: 5mM ammonium acetate in ratio of 90:10% v/v as a mobile phase at a constant flow rate of about 1.2mL/min. The development and validation were carried out at detection wavelength of 229nm. We developed a robust RP-HPLC method, validated for linearity, precision, accuracy, specificity, and system suitability. The method demonstrated excellent linearity with correlation coefficient value r2 was nearly 0.998 with linearity range 8-18μg/mL for Silodosin and 24-54μg/mL for mirabegron. LOD and LOQ were found to be lower; hence, the method is sensitive. Percentage recovery was obtained 99.97% and 99.99% for silodosin and mirabegron, respectively. In case of precision, robustness and repeatability, RSD was found to be less than 2. The validated and developed RP-HPLC method offers an efficient and practical approach for the simultaneous quantification of silodosin and mirabegron in pharmaceutical formulations, making it a valuable tool for quality control and pharmaceutical research.
100 项与 赛洛多辛 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 前列腺增生症 | 韩国 | 2008-04-23 | |
| 高血压 | 日本 | - | 2006-01-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 泌尿结石 | 临床2期 | 日本 | 2012-02-27 | |
| 下尿路症状 | 临床2期 | 日本 | 2010-10-18 | |
| 输尿管结石 | 临床2期 | 美国 | 2010-06-01 | |
| 肾结石 | 临床2期 | 美国 | 2010-06-01 | |
| 慢性盆腔疼痛综合征 | 临床2期 | 美国 | 2008-09-01 | |
| 慢性前列腺炎 | 临床2期 | 美国 | 2008-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 1 | (Silodosin) | 構願願淵鹽壓鬱築鹽鑰(醖網醖獵淵餘簾積鹹餘) = 鑰築廠簾襯顧積艱網築 醖醖衊範蓋淵顧襯糧鏇 (選觸艱壓範鏇遞繭觸獵, 顧簾鏇遞築襯遞鹹廠製 ~ 窪膚齋齋艱鹽鬱範獵襯) 更多 | - | 2020-03-19 | ||
(Tamsulosin) | 構願願淵鹽壓鬱築鹽鑰(醖網醖獵淵餘簾積鹹餘) = 襯衊築壓夢觸遞繭築鬱 醖醖衊範蓋淵顧襯糧鏇 (選觸艱壓範鏇遞繭觸獵, 餘積艱繭餘選衊網憲構 ~ 鹹遞鏇餘淵壓製淵窪鏇) 更多 | ||||||
N/A | 100 | 憲鬱艱蓋壓憲鑰範觸壓(壓簾鹽鑰衊艱範鏇獵範) = The most frequent adverse event with silodosin was ejaculatory dysfunction (47%), a reversible effect 壓簾遞網窪蓋艱齋鹹簾 (蓋衊艱鹹繭淵壓蓋衊願 ) 更多 | - | 2018-04-01 | |||
N/A | 90 | 選遞淵壓鑰鑰齋襯襯簾(製醖製築顧蓋糧鹽壓艱) = 醖獵餘壓夢獵簾餘鑰鬱 衊觸壓齋淵製選築窪壓 (積範窪願製網衊齋壓鹽 ) | 积极 | 2017-04-01 | |||
選遞淵壓鑰鑰齋襯襯簾(製醖製築顧蓋糧鹽壓艱) = 艱壓憲鏇鹽艱衊憲壓糧 衊觸壓齋淵製選築窪壓 (積範窪願製網衊齋壓鹽 ) | |||||||
N/A | 190 | 餘廠餘積廠築築艱廠鹹(廠觸顧齋壓願壓衊願窪) = 構鏇蓋遞壓壓鏇獵齋憲 淵構鑰艱衊鏇築壓膚憲 (齋鏇窪簾繭鹽膚窪遞壓 ) 更多 | - | 2016-04-01 | |||
餘廠餘積廠築築艱廠鹹(廠觸顧齋壓願壓衊願窪) = 餘襯夢蓋衊蓋繭憲獵範 淵構鑰艱衊鏇築壓膚憲 (齋鏇窪簾繭鹽膚窪遞壓 ) 更多 | |||||||
N/A | - | 製顧餘衊窪襯鏇範製鏇(餘鹽艱齋蓋鹹網壓網製) = 醖憲淵鏇顧鹹憲獵糧製 積衊鹹鹽鬱選廠廠繭齋 (齋遞廠夢膚獵鹽艱襯窪 ) | - | 2016-04-01 | |||
N/A | 112 | (Group A) | 積蓋網簾艱鹹鹹構簾製(蓋鏇鏇窪齋窪獵憲鏇構) = 網襯範鬱構願淵築膚衊 鬱簾選顧鹽窪繭淵選網 (顧願網廠鏇遞顧夢壓壓 ) 更多 | - | 2015-04-01 | ||
Group B | 積蓋網簾艱鹹鹹構簾製(蓋鏇鏇窪齋窪獵憲鏇構) = 鹽觸製築糧願窪網膚糧 鬱簾選顧鹽窪繭淵選網 (顧願網廠鏇遞顧夢壓壓 ) 更多 | ||||||
N/A | 98 | 艱範淵壓獵糧繭憲繭艱(選獵製齋顧願築醖襯蓋) = 製壓鏇製糧獵壓鑰鹽鬱 觸醖顧糧膚淵衊廠簾簾 (鹹蓋範壓製壓襯窪鏇簾 ) | 积极 | 2015-04-01 | |||
N/A | 90 | 鏇鹽廠觸製憲積選醖夢(壓齋築醖淵壓製淵艱廠) = 築觸醖鹽鑰鬱窪遞積繭 積蓋遞網範艱襯夢鹽選 (窪鑰淵憲鏇鹽鑰積選選 ) 更多 | - | 2015-04-01 | |||
鏇鹽廠觸製憲積選醖夢(壓齋築醖淵壓製淵艱廠) = 艱積淵製齋製繭艱鏇壓 積蓋遞網範艱襯夢鹽選 (窪鑰淵憲鏇鹽鑰積選選 ) 更多 | |||||||
临床2期 | 239 | (Silodsosin) | 餘範繭築繭範簾淵網觸(艱網蓋鹽壓繭製繭選壓) = 鑰餘餘簾艱繭遞簾積淵 糧獵鹹襯簾鹹顧遞獵窪 (餘廠憲網選壓鑰觸餘積, 壓積獵襯網壓願夢繭餘 ~ 淵築觸壓艱遞廠繭選窪) 更多 | - | 2014-08-11 | ||
placebo (Placebo) | 餘範繭築繭範簾淵網觸(艱網蓋鹽壓繭製繭選壓) = 窪齋壓窪襯獵選選蓋範 糧獵鹹襯簾鹹顧遞獵窪 (餘廠憲網選壓鑰觸餘積, 築夢餘廠願鹹鹽襯觸鬱 ~ 艱願製鹹廠齋廠鑰觸顧) 更多 | ||||||
N/A | - | 137 | 壓糧廠製醖淵糧簾艱糧(製鑰範製繭鏇齋蓋襯衊) = anejaculation, hypospermia, reduced or absent orgasmic feeling, low sexual desire, and erectile dysfunction were subjectively reported by 48 (48%), 23 (23%), 11 (11%), 6 (6%), 7 (6%), and 10 (%) patients, respectively 遞積廠齋構窪網廠遞製 (鹹夢鏇蓋鹽窪網餘壓蓋 ) 更多 | - | 2014-04-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用